The gut-lung axis in the CFTR modulator era

Frontiers in Cellular and Infection Microbiology

Cellular and Infection Microbiology

Maxime Lefranc¹  Éléna Charpentier²  Florian Lussac-Sorton²  Patrick Berger³  Laurence Delhaes³  Raphaël Enaud³  Stéphanie Bui³  Michael Fayon³  Sébastien Imbert³ 

[1] CHU Bordeaux, Service de Parasitologie et Mycologie, Centre de Ressources et de Compétences de la Mucoviscidose (CRCM), Service de Pédiatrie, Service d’Exploration Fonctionnelle Respiratoire, CIC, Bordeaux, France;Univ. Bordeaux, Centre de Recherche Cardio-Thoracique de Bordeaux, INSERM U1045, Pessac, France;INSERM, Centre de Recherche Cardio-thoracique de Bordeaux, Pessac, France;Univ. Bordeaux, Centre de Recherche Cardio-Thoracique de Bordeaux, INSERM U1045, Pessac, France;INSERM, Centre de Recherche Cardio-thoracique de Bordeaux, Pessac, France;CHU Bordeaux, Service de Parasitologie et Mycologie, Centre de Ressources et de Compétences de la Mucoviscidose (CRCM), Service de Pédiatrie, Service d’Exploration Fonctionnelle Respiratoire, CIC, Bordeaux, France;

关键词: gut-lung axis;    microbiota;    mycobiota;    cystic fibrosis;    CFTR modulators;   

DOI  :  10.3389/fcimb.2023.1271117

 received in 2023-08-01, accepted in 2023-08-30,  发布年份 2023

来源: Frontiers

【 摘 要 】

The advent of CFTR modulators represents a turning point in the history of cystic fibrosis (CF) management, changing profoundly the disease’s clinical course by improving mucosal hydration. Assessing changes in airway and digestive tract microbiomes is of great interest to better understand the mechanisms and to predict disease evolution. Bacterial and fungal dysbiosis have been well documented in patients with CF; yet the impact of CFTR modulators on microbial communities has only been partially deciphered to date. In this review, we aim to summarize the current state of knowledge regarding the impact of CFTR modulators on both pulmonary and digestive microbiomes. Our analysis also covers the inter-organ connections between lung and gut communities, in order to highlight the gut-lung axis involvement in CF pathophysiology and its evolution in the era of novel modulators therapies.

【 授权许可】

Unknown   
Copyright © 2023 Lussac-Sorton, Charpentier, Imbert, Lefranc, Bui, Fayon, Berger, Enaud and Delhaes